EMA approved orphan medicines since the implementation of the orphan legislation
Abstract Background In the European Union (EU), the orphan legislation, aiming to increase the number of pharmacotherapies available for rare diseases, came into force in April 2000. This study examined the development of the selection of orphan medicines granted marketing authorisation, their appro...
Saved in:
| Main Authors: | Eveliina Hahl, Terhi Kurko, Hanna Koskinen, Marja Airaksinen, Kati Sarnola |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-025-03756-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The clinical assessment of studies on orphan drugs in relation to the EMA’s authorization marketing decisions in Europe
by: Szczepan Jakubowski, et al.
Published: (2025-03-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01) -
Has OMP legislation been successful? Yes, though the orphan drug market remains immature
by: Oriol Solà-Morales
Published: (2019-01-01) -
Optimizing Patient Access to Orphan Medicinal Products: Lessons from Central and Eastern Europe
by: Tomasz Kluszczynski, et al.
Published: (2025-05-01) -
Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01)